期刊文献+

水溶性铂类抗肿瘤药的合成与体外抗肿瘤活性评价 被引量:4

Preparation of Highly Water-soluble Platinum Antitumor Drugs and Evaluation of Antitumor Efficacy on Tumor Cell Lines
原文传递
导出
摘要 目的设计并合成高水溶性铂类抗肿瘤化合物,通过体外抗肿瘤细胞毒性研究证明其抗肿瘤药效。方法以氯亚铂酸钾为起始原料制备络合氨(胺)基二碘合铂,并与Ag2SO4反应得中间体Ⅰ,中间体Ⅱ为2-氨基或N-取代氨基烷基丙二酸二钠,两者按1∶1在酸性条件下反应得到目标化合物Ⅲ。结果成功合成了一类新型结构的铂类化合物,其水溶性明显优于现有的三代铂类化合物。新化合物对多种肿瘤细胞株显示了抗肿瘤药效,作用强于卡铂;其中Ⅲg在一些肿瘤细胞株的作用与顺铂相当;而且一些化合物对顺铂耐药株有效。结论目标化合物Ⅲg作为进入临床研究的高水溶性铂类抗肿瘤候选药,体外实验证明其具有良好的抗肿瘤药效,小鼠体内半数致死量实验显示毒性小于顺铂和卡铂。 OBJECTIVE To design and synthesize a new kind of highly water-soluble platinum antitumor compounds,and then evaluate their cytotoxicity in order to confirm their antitumor efficacy.METHODS Diamide-diiodide platinum was firstly synthesized from potassium chloroplatinate,which was then reacted with Ag2 SO4 to obtain intermediateⅠ.Using disodium 2-amino-alkyl malonate or N-substituted amino alkyl malonate as the intermediateⅡ,the two intermediates reacted at 1∶1 molar ratio to obtain the target compoundⅢin the presence of acid.RESULTS A new class of platinum compounds were synthesized,which had much better water solubility than that of the existing three-generation platinum compounds.Their antitumor efficacy was confirmed against a variety of tumor cell lines which was higher than that of carboplatin.Ⅲgwas similar to cisplatin in antitumor efficacy on some tumor cell lines.Some target compounds were effective against cisplatin-resistant cell lines.CONCLUSION Currently in the clinical trial,the target compoundⅢgis a new platinum-base antitumor candidate,which exhibits good water solubility and antitumor efficacy in vitro,and the LD50 based on mice shows its lower toxicity than that of cisplatin and carboplatin in vivo.
作者 陈卓 孟小平 任永会 高泽军 CHEN Zhuo;MENG Xiao-ping;REN Yong-hui;GAO Ze-jun(Beijing Showby Pharma Sci&Tech Ltd.Co.,Beijing 101102,China;Beijing Fengshuo Weikang Technology Development Ltd.Co.,Beijing 101102,China)
出处 《中国药学杂志》 CAS CSCD 北大核心 2020年第1期8-13,共6页 Chinese Pharmaceutical Journal
基金 科技部“十一五”科技重大专项课题资助(2009ZX09103-114) 北京市首都市民健康项目资助(111102058511008) 北京G20工程医药产业创新研发资助(Z18100002218021)
关键词 Pt(0506)101 顺铂 卡铂 奥沙利铂 药物合成 溶解度 体外抗肿瘤药效 半数致死量 Pt(0506)101 cisplatin carboplatin oxaliplatin drug synthesis solubility in vitro antitumor efficacy LD50
  • 相关文献

参考文献1

二级参考文献75

  • 1Sersa G, Stabuc B, Cemazar M, Miklavcic D, Rudolf Z. Electrochemotherapy with cisplatin: Clinical experience in malignant melanoma patients. Clin Cancer Res 2000; 6(3): 863 -7.
  • 2Alcindor T, Beauger N. Oxaliplatin: A review in the era of molecularly targeted therapy. Curr Onco12011; 18(1): 18-25.
  • 3Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy- naive patients with advanced-stage non-small-cell lung cancer. J Clin Onco12008:26(21): 3543-51.
  • 4Vogelzang NJ, Rusthoven J J, Symanowski J, Denham C, Kaukel E, Ruffle P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Onco12003; 21(14): 2636-44.
  • 5Chang CL, Hsu YT, Wu CC, Lai YZ, Wang C, Yang YC, et al. Dose-dense chemotherapy improves mechanisms of antitumor immune response. Cancer Res 2013; 73(1): 119-27.
  • 6Hotta K, Matsuo K, Ueoka H, Kiura K, Tabata M, Tanimoto M. Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small-cell lung cancer. J Clin Onco12004; 22(19): 3852-9.
  • 7Sandier A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non- small-cell lung cancer. N Engl J Med 2006; 355(24): 2542-50.
  • 8Yoshimura A, Noro R, Miyanaga A, Mizutani H, Kosaihira S, Minegishi Y, et al. Combination chemotherapy of alternating etoposide and carboplatin with weekly administration of irinotecan and cisplatin in extensive-stage small-cell lung cancer. Anticancer Res 2012; 32(10): 4473-8.
  • 9Socinski M, Langer C, Okamoto I, Hon J, Hirsh V, Dakhil S, et al. Safety and efficacy of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small-cell lung cancer. Ann Oncol 2013; 24(2): 314-21.
  • 10Raymond E, Chancy S, Taamma A, Cvitkovic E. Oxaliplatin: A review ofpreclinical and clinical studies. Ann Oncol 1998; 9 (10): 1053-71.

共引文献24

同被引文献28

引证文献4

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部